Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management.
Tang G, Li S, Zhang C, Chen H, Wang N, Feng Y.
Acta Pharm Sin B. 2021 Sep;11(9):2749-2767. doi: 10.1016/j.apsb.2020.12.020. Epub 2021 Feb 2.
Single-cell transcriptomics reveals a mechanosensitive injury signaling pathway in early diabetic nephropathy.
Liu S, Zhao Y, Lu S, Zhang T, Lindenmeyer MT, Nair V, Gies SE, Wu G, Nelson RG, Czogalla J, Aypek H, Zielinski S, Liao Z, Schaper M, Fermin D, Cohen CD, Delic D, Krebs CF, Grahammer F, Wiech T, Kretzler M, Meyer-Schwesinger C, Bonn S, Huber TB.
Genome Med. 2023 Jan 10;15(1):2. doi: 10.1186/s13073-022-01145-4.
Spatial-resolved metabolomics reveals tissue-specific metabolic reprogramming in diabetic nephropathy by using mass spectrometry imaging.
Wang Z, Fu W, Huo M, He B, Liu Y, Tian L, Li W, Zhou Z, Wang B, Xia J, Chen Y, Wei J, Abliz Z.
Acta Pharm Sin B. 2021 Nov;11(11):3665-3677. doi: 10.1016/j.apsb.2021.05.013. Epub 2021 May 20.
The New Biology of Diabetic Kidney Disease-Mechanisms and Therapeutic Implications.
Lytvyn Y, Bjornstad P, van Raalte DH, Heerspink HL, Cherney DZI.
Endocr Rev. 2020 Apr 1;41(2):202-31. doi: 10.1210/endrev/bnz010.
Recent therapeutic targets in diabetic nephropathy.
Mohsen M, Elberry AA, Mohamed Rabea A, Abdelrahim MEA, Hussein RRS.
Int J Clin Pract. 2021 Nov;75(11):e14650. doi: 10.1111/ijcp.14650. Epub 2021 Aug 10.
The beneficial effects of astragaloside IV on ameliorating diabetic kidney disease.
Gao Y, Su X, Xue T, Zhang N.
Biomed Pharmacother. 2023 Jul;163:114598. doi: 10.1016/j.biopha.2023.114598. Epub 2023 May 5.
Pharmacological treatment of hyperglycemia in type 2 diabetes.
Taylor SI, Yazdi ZS, Beitelshees AL.
J Clin Invest. 2021 Jan 19;131(2):e142243. doi: 10.1172/JCI142243.
Astragaloside IV ameliorates diabetic nephropathy in db/db mice by inhibiting NLRP3 inflammasome-mediated inflammation.
Feng H, Zhu X, Tang Y, Fu S, Kong B, Liu X.
Int J Mol Med. 2021 Aug;48(2):164. doi: 10.3892/ijmm.2021.4996. Epub 2021 Jul 19.
Follow-up study on urinary type IV collagen in patients with early stage diabetic nephropathy.
Iijima T, Suzuki S, Sekizuka K, Hishiki T, Yagame M, Jinde K, Saotome N, Suzuki D, Sakai H, Tomino Y.
J Clin Lab Anal. 1998;12(6):378-82. doi: 10.1002/(sici)1098-2825(1998)12:6<378::aid-jcla8>3.0.co;2-j.
Diabetic nephropathy: An update on pathogenesis and drug development.
A/L B Vasanth Rao VR, Tan SH, Candasamy M, Bhattamisra SK.
Diabetes Metab Syndr. 2019 Jan-Feb;13(1):754-762. doi: 10.1016/j.dsx.2018.11.054. Epub 2018 Nov 30.
